A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 | Zendy

David R. Boulware | Zendy; Matthew F Pullen | Zendy; Ananta Bangdiwala | Zendy; Katelyn A Pastick | Zendy; Sarah M Lofgren | Zendy; Elizabeth C Okafor | Zendy; Caleb P Skipper | Zendy; Alanna A Nascene | Zendy; Melanie R. Nicol | Zendy; Mahsa Abassi | Zendy; Nicole Engen | Zendy; Matthew P. Cheng | Zendy; Derek LaBar | Zendy; Sylvain Lother | Zendy; Lauren MacKenzie | Zendy; Glen Drobot | Zendy; Nicole Marten | Zendy; Ryan Zarychanski | Zendy; Lauren E. Kelly | Zendy; Ilan S. Schwartz | Zendy; Emily G. McDonald | Zendy; Radha Rajasingham | Zendy; Todd C. Lee | Zendy; Kathy Huppler Hullsiek | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

Author(s) -

David R. Boulware,

Matthew F Pullen,

Ananta Bangdiwala,

Katelyn A Pastick,

Sarah M Lofgren,

Elizabeth C Okafor,

Caleb P Skipper,

Alanna A Nascene,

Melanie R. Nicol,

Mahsa Abassi,

Nicole Engen,

Matthew P. Cheng,

Derek LaBar,

Sylvain Lother,

Lauren MacKenzie,

Glen Drobot,

Nicole Marten,

Ryan Zarychanski,

Lauren E. Kelly,

Ilan S. Schwartz,

Emily G. McDonald,

Radha Rajasingham,

Todd C. Lee,

Kathy Huppler Hullsiek

Publication year - 2020

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2016638

Subject(s) - hydroxychloroquine , medicine , placebo , asymptomatic , face shield , pre exposure prophylaxis , randomized controlled trial , covid-19 , confidence interval , incidence (geometry) , disease , virology , pathology , health care , human immunodeficiency virus (hiv) , men who have sex with men , physics , alternative medicine , syphilis , infectious disease (medical specialty) , optics , economics , economic growth

Coronavirus disease 2019 (Covid-19) occurs after exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). For persons who are exposed, the standard of care is observation and quarantine. Whether hydroxychloroquine can prevent symptomatic infection after SARS-CoV-2 exposure is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research